Johnson & Johnson: Opportunity in Passive Income Investment!

Johnson & Johnson (NYSE:JNJ) is currently among the top 15 passive income stocks to acquire. Scotiabank analyst Louise Chen emphasized on November 12, in her assessment of large-cap biopharma companies, that the sector presents attractive opportunities for the future. She noted that the long-standing underperformance compared to other industries and major indicators could provide a suitable entry point for investors. Chen pointed out that companies seeking real treatment solutions for serious diseases may stand out in the innovative phase.

Chen marked Johnson & Johnson as the best choice, stating that the company's efforts in therapeutic methods and its consistently successful applications enhance its growth potential. Scotiabank continues to give this stock an Outperform rating.

Johnson & Johnson (NYSE:JNJ) has a rare dividend history. The company has managed to increase its dividend for 63 consecutive years. Despite facing challenges such as patent expirations, its extensive drug portfolio continues to provide consistent growth. This year, although they lost U.S. exclusivity for a major immunology drug called Stelara, revenues and earnings continued to rise. Third-quarter sales reached $24 billion, an increase of 6.8% compared to the same period last year.

Johnson & Johnson (NYSE:JNJ) operates globally and focuses on two main areas: Innovative Medicine and MedTech.

When evaluating this investment, we believe that some artificial intelligence stocks may present greater potential and carry less risk. If you are looking for an artificial intelligence stock that has significantly depreciated and can benefit from tariffs imposed during the Trump administration, check out our free report containing the best short-term artificial intelligence stock for you.